OREANDA-NEWS. SCYNEXIS, Inc. and JSC R-Pharm today announced an agreement that provided R-Pharm with exclusive rights for development and marketing of SCY-078 in Russia and other countries. SCYNEXIS retains rights for distribution of the drug in America, Europe and Asia. SCY-078 is a peroral glycosynthase inhibitor designed for treatment of systemic mycoses including candidemia and aspergillosis.

“Glycosynthase inhibitors are found highly efficient for hospital treatment of invasive mycosis. However these drugs used to be available in a form of intravenous injection only,” said Alexey Repik, Chairman, R-Pharm Group. “SCY-078 is the first peroral glycosynthase inhibitor that makes it highly demanded by both healthcare organizations and patients, when echinocandin IV injections don't meet therapy requirements.”

“Partnership with JSC R-Pharm is an important milestone in transition to clinical trials Stage II and further development of SCY-078,” said Dr. Yves Ribeill, President and Executive Director, SCYNEXIS. “We appreciate the role of R-Pharm in development and distribution of SCY-078. This partnership opens several important and promising markets, including Russia.”

According to the agreement JSC R-Pharm will take care of development and registration of SCY-078 in several regions, including Russia, CIS and Turkey. SCYNEXIS will receive a deposit and keep rights for royalty and further development and marketing payments. No more details of the agreement were disclosed.